eMedicine Specialties > Psychiatry > Emergency

Neuroleptic Malignant Syndrome

Joseph Tonkonogy, MD, PhD, Clinical Professor of Psychiatry and Neurology, University of Massachusetts Medical School; Consulting Staff, Departments of Psychiatry and Neurology, University of Massachusetts Medical Center
Darius P Sholevar, MD, Fellow, Cardiovascular Disease, Albert Einstein Medical Center

Updated: May 7, 2009

Introduction

Background

Neuroleptic malignant syndrome (NMS) refers to the combination of hyperthermia, rigidity, and autonomic dysregulation that can occur as a serious complication of the use of antipsychotic drugs. Delay first used the term in 1960, after observing patients treated with high-potency antipsychotics.¹

Even the newer atypical antipsychotics, which are not classified accurately as neuroleptics, can cause neuroleptic malignant syndrome. Over the past 30 years, the syndrome has been associated with a variety of drugs that lead to decreased dopamine receptor activation.

While some clear risk factors for neuroleptic malignant syndrome are present, the low incidence of this syndrome and the consequent difficulty in studying it in a controlled, prospective manner make clinical features, predisposing conditions, treatment, and prognosis difficult to define.

Following is a case vignette of a patient with neuroleptic malignant syndrome that developed several days after the start of treatment with the atypical antipsychotic olanzapine.

A 66-year-old white male was hospitalized for increasingly aggressive behavior. He had no prior psychiatric admissions. On the day of admission after he sustained a fall, a CT scan of the brain revealed a subarachnoid hemorrhage at the right superior sulcus and a possible hemorrhagic contusion at the left frontal lobe. Over the course of hospitalization, the patient had a series of CT scans showing resolution of the hemorrhage. He was started on olanzapine for intermittent agitation. Olanzapine was titrated to 7.5 mg daily.

Ten days later the patient became abruptly somnolent with body temperature reaching 39.7 º C and severe muscle rigidity in both upper and lower extremities. He had severe diaphoresis and fluctuation of blood pressure and pulse. Laboratory data revealed elevation of white blood cells to 14800 K/L, creatine phosphokinase to 2800 U/L (normal <174 U/L), and mild elevation of serum alanine and aspartate aminotransferase. MRI of the brain, CSF studies, and chest radiograph were unremarkable. A presumptive diagnosis of neuroleptic malignant syndrome was made. Olanzapine was immediately discontinued and supportive care was initiated.

Intravenous lorazepam was given as needed every 4 hours for behavioral agitation along with a fixed 0.5 mg intravenous push twice daily. The patient received a total of 8.5 mg of lorazepam in the first 24 hours and 3 mg the next day. Fever and muscular rigidity resolved in 24 hours. All other manifestations of neuroleptic malignant syndrome resolved in 9 days.

Pathophysiology

The most widely accepted mechanism by which antipsychotics cause neuroleptic malignant syndrome is that of dopamine D2 receptor antagonism. In this widely accepted model, central D2 receptor blockade in the hypothalamus, nigrostriatal pathways, and spinal cord leads to increased muscle rigidity and tremor via extrapyramidal pathways. Hypothalamic D2 receptor blockade results in an elevated temperature set point and impairment of heat-dissipating mechanisms. Peripherally, antipsychotics lead to increased calcium release from the sarcoplasmic reticulum, resulting in increased contractility, which can contribute to hyperthermia, rigidity, and muscle cell breakdown.

Beyond these direct effects, D2 receptor blockade might cause neuroleptic malignant syndrome by removing tonic inhibition from the sympathetic nervous system. The resulting sympathoadrenal hyperactivity and dysregulation leads to autonomic dysfunction. This model suggests that patients with baseline high levels of sympathoadrenal activity might be at increased risk. While this has not been proven in controlled studies, several such states have been proposed as risk factors for neuroleptic malignant syndrome.²

Direct muscle toxicity also has been proposed as a mechanism of neuroleptic malignant syndrome.

Frequency

United States

Neuroleptic malignant syndrome is associated with the use of various antipsychotic medicines, most frequently the older antipsychotics, termed neuroleptics. Development of neuroleptic malignant syndrome appears to be independent of the conditions that these medicines treat.

The syndrome can occur after any duration of treatment, although two thirds of cases occur within the first week. The frequency has been variably reported as 0.07–2.2% of patients taking neuroleptics.³ Data largely come from case control studies rather than prospective randomized trials.

International

The frequency of neuroleptic malignant syndrome internationally parallels the use of antipsychotics, especially neuroleptics, in a given region. No data suggest geographic or racial variation. The one large randomized trial conducted in China showed an incidence of 0.12% in patients taking neuroleptics.⁴ A retrospective study conducted in India showed an incidence of 0.14%.⁵

Mortality/Morbidity

Mortality from neuroleptic malignant syndrome is very difficult to quantify due both to the case report designs of most of the literature and to the inconsistency of the diagnostic parameters used.

• In some series, mortality rates as high as 76% have been reported. Most series suggest, however, that the mortality rate is 10-20%. When reporting bias is factored in, the true rate of mortality from neuroleptic malignant syndrome might be much lower.
• Studies have also found that the mortality rate has been decreasing over the past 2 decades. Mortality is generally higher in patients who develop severe muscle necrosis and resulting rhabdomyolysis.

Race

No data suggest geographic or racial variation.

Sex

Incidence is higher in males.

Age

• Incidence is higher in persons younger than 40 years. Differential incidence simply might reflect a population that has a high rate of antipsychotic usage.
• Some small case series looking at neuroleptic malignant syndrome in elderly patients suggest that onset might occur after a longer duration of antipsychotic use.
• Studies in children suggest that clinical presentation might be somewhat different.

Clinical

History

• Criteria for the diagnosis of neuroleptic malignant syndrome are based on clinical features. Cardinal features are the development of severe muscular rigidity, hyperthermia, autonomic instability, and changes in the level of consciousness associated with the use of an antipsychotic medication, most often a neuroleptic.
• In addition to hyperthermia and rigidity, at least 2 other clinical features of neuroleptic malignant syndrome, including leukocytosis and laboratory evidence of muscle injury, should be present.
• The key to diagnosis is that symptoms occur only after exposure to antipsychotics. Symptoms should improve after the antipsychotic is stopped. No new focal neurological deficits should develop, although cases of neurological sequelae have been reported rarely.
• A summary of the clinical features of neuroleptic malignant syndrome includes the following:
  • Diaphoresis
  • Dysphagia
  • Tremor
  • Incontinence
  • Delirium progressing to lethargy, stupor, coma
• Labile blood pressure
• Pallor
• Dyspnea
• Psychomotor agitation
• Rigidity
• Hyperthermia
• Tachycardia
• Shuffling gait
• For accurate diagnosis, rule out reaction to another medication or medical condition that might be a more likely cause of the symptoms than use of an antipsychotic.
• Various other medications cause conditions that are indistinguishable from neuroleptic malignant syndrome and likely involve similar chemical structure and the same pathophysiology. All of these agents, including metoclopramide, prochlorperazine, promethazine, and droperidol, cause decreased dopamine receptor activation.
• A similar syndrome also has been associated with the rapid removal of medications with dopaminergic properties (eg, in patients treated for Parkinson disease).⁶ Medications in these classes often are used to treat Parkinson disease and include levodopa, bromocriptine, and amantadine. Dopaminergic drugs should be started as soon as possible to prevent rhabdomyolysis and renal failure.⁷
• Lethal catatonia (LC) is a similar condition that might be confused with neuroleptic malignant syndrome. Lethal catatonia occurs in people with schizophrenia or during manic episodes. Neuroleptics might either improve or worsen the symptoms of lethal catatonia. Distinguishing lethal catatonia from neuroleptic malignant syndrome can be difficult, although a detailed history might reveal episodes of catatonia while a patient is not taking neuroleptics. Lethal catatonia also tends to have a prodrome of excitement and agitation prior to the onset of rigidity, while neuroleptic malignant syndrome tends to begin with rigidity.⁸
• Antipsychotics can cause a variety of reactions that can be confused with neuroleptic malignant syndrome. These reactions often occur with increasing medication dosages. Neuroleptic-induced acute dystonia is an abnormal contraction or spasm of a group of skeletal muscles, often involving the head or neck. Neuroleptic-induced acute akathisia is motor restlessness, particularly involving the legs. Neuroleptic-induced tardive dyskinesia involves involuntary, rhythmic movements starting with mouth movements. Neuroleptic-induced parkinsonism, or pseudoparkinsonism, presents with the classic triad of tremor, muscular rigidity, and akinesia. Despite the term neuroleptic-induced, these conditions also can be caused, although less frequently, by many of the newer, nontraditional antipsychotic medications as well. In future editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM), the terminology might be changed to include nonneuroleptic antipsychotics.
• The serotonin syndrome is very similar to neuroleptic malignant syndrome. The triad of (1) altered mental status, (2) autonomic dysfunction, and (3) neuromuscular abnormalities that occurs on exposure to serotonergic agents characterizes the serotonin syndrome. Selective serotonin reuptake inhibitors (SSRIs) are the most frequently used medications in this class. The proposed mechanism is excessive 5-hydroxytryptamine (5-HT or serotonin) stimulation. Given the increasing use of the SSRIs, the serotonin syndrome might become increasingly prevalent. The serotonin syndrome can be distinguished from neuroleptic malignant syndrome in most cases by a detailed history of medication use with particular attention to recent dosage changes and the absence of severe rigidity. Treatment of this condition includes removal of the offending drug and supportive management, though 5-HT1A antagonists might have a role in the future.^9,10
• Medication-induced movement disorders not otherwise specified can be very similar to neuroleptic malignant syndrome but occur on exposure to other psychotropic medications. Malignant hyperthermia (MH) occurs after administration of halogenated inhalational anesthetics, such as halothane, and depolarizing muscle relaxants, such as succinylcholine, to genetically susceptible individuals. An underlying defect is an autosomal dominant mutation in the ryanodine receptor, which leads to excessive calcium release from the sarcoplasmic reticulum in skeletal muscle when one of the above agents is administered. A multifactorial pattern of inheritance also has been postulated. Malignant hyperthermia can be distinguished readily by history. Treatment is based on supportive care, use of dantrolene to decrease calcium release, and avoidance of precipitating medications. No evidence shows that neuroleptic malignant syndrome occurs more frequently in patients susceptible to malignant hyperthermia.
• Heat stroke can cause a similar picture, but patients have dry skin and flaccidity in addition to hyperthermia and hypotension.
• General medical conditions that might mimic neuroleptic malignant syndrome include central nervous system infections, status epilepticus, stroke, brain trauma, neoplasms, acute intermittent porphyria, and tetanus.
• Laboratory abnormalities observed in neuroleptic malignant syndrome have broad differential diagnoses and only specific points are presented in this chapter (see Lab Studies). Elevated creatine kinase (CK) can be observed with intramuscular injections and the use of restraints. Leukocytosis occurs with central nervous system infections.

Physical

Neuroleptic malignant syndrome tends to start with muscular rigidity and progress to hyperthermia with autonomic instability and a fluctuating level of consciousness. Compared to disease in adults, neuroleptic malignant syndrome in children and adolescents tends to present with more dystonia and less tremor.

• Symptoms of autonomic dysregulation include high fever, diaphoresis, tachypnea, tachycardia, and increased or labile blood pressure. In rare cases, a reversible cardiomyopathy mimicking cardiac infarction may develop the autonomic involvement in the course of neuroleptic malignant syndrome.¹¹
• Extrapyramidal symptoms include so-called lead pipe rigidity; dysphagia; a short, shuffling gait; resting tremor; dystonia; and dyskinesia.
• Excessive or purposeless motor activity and tremor can reflect psychomotor agitation.
• Delirium is characterized by the following:
  • Loss of awareness
  • Detachment from both the inside and outside worlds
  • Loss of orientation in time and space
  • Reduced ability to sustain the attention that wanders around and can not be directed at will
  • Speech that is often mumbled and incoherent
  • Development of illusions and hallucinations, especially visual
  • Level of consciousness fluctuates but may eventually decrease to the stages of lethargy, stupor, or coma
• Other features include pallor, rash, and dyspnea.

Causes

All classes of antipsychotics have been associated with neuroleptic malignant syndrome, including low-potency neuroleptics, high-potency neuroleptics, and the newer (or atypical) antipsychotics. Neuroleptic malignant syndrome has been reported most frequently in patients taking haloperidol and chlorpromazine.

• The clearest risk factors relate to the time course of therapy. Strongly associated factors are the use of high doses of antipsychotics (particularly the high-potency neuroleptics), rapid antipsychotic dosage increases, and the use of depot, the long-acting injectable forms of antipsychotics.¹² In the United States, only 3 long-acting forms are available at present—fluphenazine decanoate or enanthate, haloperidol decanoate, and risperdal consta.
• Other factors related to a patient's pharmacotherapy might be relevant, although their role has not been proven in controlled studies. Inconsistent use of neuroleptics and the use of other psychotropic medications, particularly lithium, have been suggested as risk factors. Prior treatment with electroconvulsive therapy (ECT) also has been proposed to have a role.
• Environmental and psychological factors that might predispose to neuroleptic malignant syndrome are hot and humid conditions, agitation, dehydration, and exhaustion.
• A number of demographic features have been implicated, many of which simply might reflect populations that have a high rate of neuroleptic usage. These include male sex and age younger than 40 years. Neuroleptic malignant syndrome has been reported in postpartum women.
• Genetic factors also might play a role. Case reports have been published on neuroleptic malignant syndrome occurring in identical twins as well as in a mother and 2 of her daughters¹³ .
• Patients who have experienced episodes of neuroleptic malignant syndrome previously are at risk for recurrences. The risk of recurrence is strongly related to the elapsed time between an episode of neuroleptic malignant syndrome and restarting antipsychotics.
  • If patients are rechallenged with antipsychotics within 2 weeks of an episode of neuroleptic malignant syndrome, 63% will have a recurrence. If more than 2 weeks have elapsed, only 30% will have a recurrence.
  • Eighty-seven percent of patients who develop neuroleptic malignant syndrome will be able to tolerate an antipsychotic at some point in the future. Given the present understanding of this syndrome, on reintroducing an antipsychotic, switch to a different antipsychotic class and, if possible, use an atypical antipsychotic because these might be less likely than traditional neuroleptics to cause neuroleptic malignant syndrome.
• A summary of medications that may induce movement disorders includes the following:
  • MAOIs
  • MAOIs combined with tricyclic antidepressants
  • MAOIs combined with serotonergic agents
  • MAOIs combined with meperidine
  • Lithium at toxic levels
  • Anticholinergics
  • Amphetamines
  • Fenfluramine
  • Cocaine
  • Phencyclidine
  • 3,4-Methylenedioxymethamphetamine (MDMA; ecstasy, XTC)
  • Methylphenidate¹⁴
• A summary of the well supported risk factors for neuroleptic malignant syndrome includes the following:
  • High-potency neuroleptic use
  • High-dose neuroleptic use
  • Rapid increase in neuroleptic dose
  • Depot injectable neuroleptic use
  • Prior episodes of neuroleptic malignant syndrome
  • Age younger than 40 years
  • Male sex
• A summary of the potential risk factors for neuroleptic malignant syndrome includes the following:
  • Dehydration¹⁵
  • Agitation¹⁵
  • Exhaustion
  • Malnutrition
  • Organic brain syndromes
  • Nonschizophrenic mental illness
  • Lithium use
  • Past history of electroconvulsive therapy
  • Warm and humid environments
  • Inconsistent use of neuroleptics
  • Postpartum period¹⁶

Differential Diagnoses

Schizophrenia

Other Problems to Be Considered

Manic-depressive illness
Lethal catatonia
Neuroleptic-induced acute dystonia
Neuroleptic-induced acute akathisia
Neuroleptic-induced tardive dyskinesia
Neuroleptic-induced parkinsonism
Serotonin syndrome
Malignant hyperthermia¹⁷
Heat stroke
Central nervous system infections
Status epilepticus
Stroke
Brain trauma
Neoplasms
Acute intermittent porphyria
Tetanus

Workup

Laboratory Studies

• The rigidity and hyperthermia found in neuroleptic malignant syndrome contribute to muscle damage and necrosis. Elevated blood CK, aminotransferases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]), and lactate dehydrogenase (LDH) reflect damage and necrosis, which can progress quickly to rhabdomyolysis with hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Elevated blood levels of myoglobin and myoglobinuria can be observed and ultimately can lead to renal failure.
• More general laboratory features include leukocytosis, thrombocytosis, and evidence of dehydration. Cerebrospinal fluid protein might be elevated. Serum iron concentration might be decreased.
• Investigate other causes for fever based on the clinical scenario.
• Investigate symptoms and signs of urinary tract, respiratory, and CNS infections.
• A summary of the laboratory abnormalities associated with neuroleptic malignant syndrome includes the following:
  • Increased LDH
  • Increased CK
  • Increased AST
  • Increased ALT
  • Increased alkaline phosphatase
  • Hyperuricemia
  • Hyperphosphatemia
  • Myoglobinemia
  • Leukocytosis
  • Thrombocytosis
  • Proteinuria
  • Decreased serum iron¹⁸
  • Increased cerebrospinal fluid (CSF) protein
  • Hypocalcemia
  • Myoglobinuria

Treatment

Medical Care

The most important intervention is to discontinue all antipsychotics. In most cases, symptoms will resolve in 1-2 weeks. Neuroleptic malignant syndrome precipitated by long-acting depot injections of antipsychotics can last as long as a month. During the course of neuroleptic malignant syndrome, use supportive care aggressively. The value of other interventions, such as dantrolene, amantadine, bromocriptine, and electroconvulsive therapy, is uncertain.¹⁹

• Supportive measures are aimed at preventing further complications and maintaining organ function.
  • Patients should receive circulatory and ventilatory support as needed.
  • Cooling blankets and antipyretics can be used to control temperature.
  • Aggressive fluid resuscitation and alkalization of urine can help prevent acute renal failure and enhance excretion of muscle breakdown products.
• Electroconvulsive therapy has been proposed as a treatment based on its effectiveness in acute lethal catatonia. Some data suggest that electroconvulsive therapy is effective for neuroleptic malignant syndrome, but serious treatment-related complications have occurred (see Complications). Specifically, patients with neuroleptic malignant syndrome have developed cardiac arrest and ventricular fibrillation after electroconvulsive therapy.

Medication

Specific drug therapies, such as dantrolene, amantadine, bromocriptine, and electroconvulsive therapy, have an uncertain role in the treatment of neuroleptic malignant syndrome. While they generally are felt to be helpful, they have been found to be deleterious in some studies.

Skeletal muscle relaxants

Modulate contractions of muscle cells.

Dantrolene (Dantrium)

Stimulates muscle relaxation by modulating skeletal muscle contractions at a site beyond myoneural junction and by acting directly on the muscle itself.
Can be administered PO/IV. IV form is much more expensive and should be reserved for patients unable to take oral medications.

Dosing

Adult

100-200 mg/d PO; not to exceed 400 mg/d
0.8-2.5 mg/kg IV q6h; not to exceed 10 mg/kg/d

Pediatric

0.5 mg/kg IV bid initially; increase to 0.5 mg/kg bid/qid; followed by increments of 0.5-3 mg/kg bid/qid prn; not to exceed 100 mg qid

Interactions

Coadministration of clofibrate and warfarin can increase toxicity; coadministration with estrogen can increase hepatotoxicity in women >35 y

Contraindications

Documented hypersensitivity; active hepatic disease (hepatitis and cirrhosis)

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Might cause hepatotoxicity (use only for recommended indications); caution in impaired pulmonary function and severe cardiac insufficiency; might cause photosensitivity with exposure to sunlight

Dopaminergic agents

In order for a dopamine agonist to offer clinical benefit, it must stimulate D2 receptors. The role of other dopamine receptor subtypes currently is unclear.

Bromocriptine (Parlodel)

Strong dopamine D2 receptor agonist and partial dopamine D1 receptor agonist. Often administered with oral dantrolene.

Dosing

Adult

5-10 mg PO bid, initial; not to exceed 40 mg/d

Pediatric

Not established

Interactions

Ergot alkaloids can increase toxicity; amitriptyline, butyrophenones, imipramine, methyldopa, phenothiazines, and reserpine can decrease bromocriptine effects

Contraindications

Documented hypersensitivity; ischemic heart disease; peripheral vascular disorders

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Orthostatic hypotension, hypotension, and nausea are major adverse effects; psychosis might occur because bromocriptine effectively can antagonize effects of neuroleptics; caution in renal or hepatic disease

Amantadine (Symmetrel)

Antiviral agent effective against influenza A. Has a proposed role in altering the release and uptake of dopamine and has been used to treat Parkinson disease. Infrequently used to treat NMS.

Dosing

Adult

100 mg PO bid; increase prn to 400 mg/d

Pediatric

<1 years: Not established
1-9 years: 5-9 mg/kg/d PO qd or divided bid
10-12 years: 100-200 mg/d PO qd or divided bid
>12 years: Administer as in adults

Interactions

Drugs with anticholinergic or CNS stimulant activity increase toxicity; concurrent administration of hydrochlorothiazide plus triamterene with amantadine can increase plasma concentrations of amantadine

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in liver disease, uncontrolled psychosis, eczematoid dermatitis, seizures, and those receiving CNS stimulant drugs; reduce dose in renal disease when treating Parkinson disease; do not discontinue abruptly

Benzodiazepines

Used in a small number of patients unresponsive to above measures. In most cases, a continuous IV infusion of diazepam or lorazepam has been utilized.

Diazepam (Valium)

Depresses all levels of CNS (eg, limbic and reticular formation) possibly by increasing activity of GABA.
Individualize dosage and increase cautiously to avoid adverse effects.

Dosing

Adult

5-10 mg PO/IV/IM q3-4h

Pediatric

0.05-0.3 mg/kg/dose IV/IM over 2-3 min q15-30min; repeat in 2-4 h prn; not to exceed 10 mg

Interactions

Coadministration of other CNS depressants, including phenothiazines, barbiturates, alcohols, and MAOIs increases toxicity of benzodiazepines in CNS

Contraindications

Documented hypersensitivity; narrow-angle glaucoma; CNS depression

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Sedation, paradoxical agitation, anxiety, amnesia, mood lability, disinhibition, ataxia, dysarthria, and nystagmus are potential adverse effects; exercise caution in patients receiving other CNS depressants; use caution also in patients diagnosed with low albumin levels or hepatic failure because diazepam toxicity might increase

Lorazepam (Ativan)

Sedative hypnotic with short onset of effects and intermediate-long half-life.
By increasing the action of GABA, which is a major inhibitory neurotransmitter in the brain, it might depress all levels of CNS, including limbic and reticular formation.

Dosing

Adult

Continuous IV infusion starting at 0.5 mg/h; maximum rate of 10 mg/h

Pediatric

Adolescents: 0.07 mg/kg IV slowly over 2-5 min; repeat in 10-15 min prn; not to exceed 4 mg/dose

Interactions

Concurrent use with alcohol, phenothiazines, barbiturates, and MAOIs increases toxicity of benzodiazepines in CNS

Contraindications

Documented hypersensitivity; preexisting CNS hypotension; depression; narrow-angle glaucoma

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Sedation, paradoxical agitation, anxiety, amnesia, mood lability, disinhibition, ataxia, and dysarthria are adverse effects; caution in renal or hepatic impairment, myasthenia gravis, cognitive impairment, or Parkinson disease

Follow-up

Complications

• Complications of neuroleptic malignant syndrome include dehydration from poor oral intake, acute renal failure from rhabdomyolysis, and deep vein thrombosis and pulmonary embolism from rigidity and immobilization.
• Avoiding antipsychotics can cause complications related to uncontrolled psychosis. Most patients taking antipsychotic medicines are being treated for a severe and persistent psychiatric disorder; a high likelihood exists that a patient will relapse while off antipsychotics.
• A summary of the potential complications of neuroleptic malignant syndrome includes the following:
  • Rhabdomyolysis
  • Renal failure
  • Cardiac arrest
  • Infection
  • Aspiration
  • Respiratory failure
  • Seizure
  • Pulmonary embolism
  • Hepatic failure
  • Uncontrolled psychoses

Prognosis

• Most series suggest that the mortality rate is 10-20%. When reporting bias is factored in, the true rate of mortality from neuroleptic malignant syndrome might be much lower. Mortality rates generally are higher in patients who develop severe muscle necrosis and resulting rhabdomyolysis.
• Patients who have previously experienced episodes of neuroleptic malignant syndrome are at risk for recurrences. The risk of neuroleptic malignant syndrome recurrence is strongly related to the elapsed time between an episode of neuroleptic malignant syndrome and restarting antipsychotics.
  • If patients are rechallenged with antipsychotics within 2 weeks of an episode of neuroleptic malignant syndrome, 63% will have a recurrence. If more than 2 weeks has elapsed, only 30% will have a recurrence.
  • Eighty-seven percent of patients who develop neuroleptic malignant syndrome will be able to tolerate another antipsychotic at some point in the future, which is very important because most patients taking neuroleptics require them to maintain a reasonable functional status. Current practice is to switch to a different class of antipsychotic when reintroducing these medications. Often, one of the newer atypical antipsychotics is chosen because current evidence suggests a lower incidence of neuroleptic malignant syndrome with these agents.

Patient Education

• Educational approaches can help patients and their relatives to understand what has happened to the patient, why the neuroleptic malignant syndrome has developed in the past, and what possibility of the recurrence of neuroleptic malignant syndrome if the patient is rechallenged with a different class of antipsychotics. This may help patients and their relatives to decide about giving consent to restart antipsychotics. They have to be aware of the early signs of developing neuroleptic malignant syndrome such as rigidity, hyperthermia, and changes of consciousness to bring attention of the medical staff to the possible redevelopment of neuroleptic malignant syndrome.
• Helpful Web sites for patients include the following:
  • Neuroleptic Malignant Syndrome Information Service
  • NINDS Neuroleptic Malignant Syndrome Information Page
  • WebMD, Neuroleptic Malignant Syndrome

Miscellaneous

Medicolegal Pitfalls

• When a patient develops neuroleptic malignant syndrome, especially when the result is fatal, physicians can be sued.
• Predicting who will develop neuroleptic malignant syndrome essentially is impossible given the current state of medical technology. Knowing that men younger than 40 years and those who previously have had neuroleptic malignant syndrome are at somewhat higher risk might help in risk stratification.
• Informed consent is particularly important before initiating treatment in these populations. Unfortunately, therapy with neuroleptics often is begun when patients are least likely to hear and interpret information accurately for informed consent, which presents a difficult area medicolegally because neuroleptic malignant syndrome is a rare but serious complication of neuroleptic therapy.
• The safest course is to provide patients and their families with as much information as they can absorb and follow up with additional information. This can be difficult to achieve in an often less-than-ideal setting.

References

1. Delay J, Pichot P, Lemperiere T, et al. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses.]. Ann Med Psychol (Paris). Jan 1960;118(1):145-52. [Medline].

2. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. Feb 1999;156(2):169-80. [Medline].

3. Gelenberg AJ, Bellinghausen B, Wojcik JD. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry. Apr 1988;145(4):517-8. [Medline].

4. Deng MZ, Chen GQ, Phillips MR. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychiatry. Sep 1990;147(9):1149-55. [Medline].

5. Chopra MP, Prakash SS, Raguram R. The neuroleptic malignant syndrome: an Indian experience. Compr Psychiatry. Jan-Feb 1999;40(1):19-23. [Medline].

6. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-40. [Medline].

7. Ward C. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study. J Neurosci Nurs. Jun 2005;37(3):160-2. [Medline].

8. Osman AA, Khurasani MH. Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis. Br J Psychiatry. Oct 1994;165(4):548-50. [Medline].

9. Martin TG. Serotonin syndrome. Ann Emerg Med. Nov 1996;28(5):520-6. [Medline].

10. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?. Curr Drug Saf. Jan 2009;4(1):84-93. [Medline].

11. Oomura M, Terai T, Sueyoshi K. Reversible cardiomyopathy as the autonomic involvement of neuroleptic malignant syndrome. Intern Med. 2004;43 (12):1162-5. [Medline]. [Full Text].

12. Keck PE Jr, Pope HG Jr, Cohen BM. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. Oct 1989;46(10):914-8. [Medline].

13. Otani K, Horiuchi M, Kondo T. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?. Br J Psychiatry. Jun 1991;158:850-3. [Medline].

14. Ehara H, Maegaki Y, Takeshita K. Neuroleptic malignant syndrome and methylphenidate. Pediatr Neurol. Oct 1998;19(4):299-301. [Medline].

15. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry. Aug 1997;154(8):1156-8. [Medline].

16. Alexander PJ, Thomas RM, Das A. Is risk of neuroleptic malignant syndrome increased in the postpartum period?. J Clin Psychiatry. May 1998;59(5):254-5. [Medline].

17. Heiman-Patterson TD. Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am. Mar 1993;77(2):477-92. [Medline].

18. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet. Jul 20 1991;338(8760):149-51. [Medline].

19. Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med. Sep 1989;149(9):1927-31. [Medline].

20. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. Aug 1987;22(8):1004-20. [Medline].

21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:735, 795-798.

22. Bertorini TE. Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Neurol Clin. Aug 1997;15(3):649-71. [Medline].

23. Borovicka MC, Bond LC, Gaughan KN. Ziprazidone and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother. 2006;40 (1):139-142. [Medline].

24. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. Jan 1993;77(1):185-202. [Medline].

25. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry. Jul 2008;69(7):1157-65. [Medline].

26. Deuschl G, Oepen G, Hermle L. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry. Jul 1987;20(4):168-70. [Medline].

27. Dickey W. The neuroleptic malignant syndrome. Prog Neurobiol. 1991;36(5):425-36. [Medline].

28. Gurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. Feb 1992;53(2):56-62. [Medline].

29. Hammerman S, Lam C, Caroff SN. Neuroleptic malignant syndrome and aripiprazole. Journal of the American Academy of Child and Adolescent Psychiatry. June 2006;45 (6):639-41. [Medline]. [Full Text].

30. Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's Synopsis of Psychiatry. Philadelphia, Pa: Lippincott, Williams, & Wilkins; 1994:1913, 2004-2005.

31. Kaufman KR, Levitt MJ, Schiltz JF, Sunderram J. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis. Ann Clin Psychiatry. Jul-Sep 2006;18(3):201-4. [Medline].

32. Keck PE Jr, Caroff SN, McElroy SL. Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy?. J Neuropsychiatry Clin Neurosci. Spring 1995;7(2):135-44. [Medline].

33. Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry. Jul 1991;148(7):880-2. [Medline].

34. Klein JP, Fiedler U, Appel H. Massive creatine kinase elevations with quetiapine: report of two cases. Pharmacopsychiatry. 2006;39(1):39-40. [Medline]. [Full Text].

35. Mendhekar DN, Jiloha RC. Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation. Aust N Z J Psychiatry. 2005;39 (10):947-8. [Medline]. [Full Text].

36. Miyaoka H, Shishikura K, Otsubo T. Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype?. Am J Psychiatry. Jun 1997;154(6):882. [Medline].

37. Rodriguez OP, Dowell MS. A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole. Journal-Oklahoma State Medical Association. July-August 2006;99(7):435-8. [Medline]. [Full Text].

38. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. Jun 1989;146(6):717-25. [Medline].

39. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?. Br J Psychiatry. Nov 1991;159:709-12. [Medline].

40. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients [published erratum appears in J Clin Psychiatry 1989 Dec;50(12):472]. J Clin Psychiatry. Aug 1989;50(8):295-8. [Medline].

41. Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics. Jan-Feb 2009;50(1):8-15. [Medline].

42. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. Jan 1989;50(1):18-25. [Medline].

43. Silva RR, Munoz DM, Alpert M. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry. Feb 1999;38(2):187-94. [Medline].

44. Trutia A, Bledowski J, Pandurangi A, Kahn DA. Neuroleptic rechallenge with aripiprazole in a patient with previously documented neuroleptic malignant syndrome. J Psychiatr Pract. Nov 2008;14(6):398-402. [Medline].

45. Vancaester E, Santens P. Catatonia and neuroleptic malignant syndrome: two sides of a coine?. Acta Neurological Belgica. June 2007;107(2):47-50. [Medline]. [Full Text].

46. Warwick TC, Moningi V, Jami P, Lucas K, Molokwu O, Moningi S. Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine. Nature Clinical Practice Neurology. March 2008;4(3):170-4. [Medline]. [Full Text].

47. Wells AJ, Sommi RW, Crismon ML. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm. Jun 1988;22(6):475-80. [Medline].

Keywords

neuroleptic malignant syndrome, antipsychotics, NMS, drug-induced movement disorder, lethal catatonia, neuroleptic-induced acute dystonia, neuroleptic-induced akathisia, neuroleptic-induced parkinsonism, neuroleptic-induced tardive dyskinesia, serotonin syndrome, hyperthermia, rigidity, autonomic dysregulation, 3, 4-methylenedioxymethamphetamine, MDMA, ecstasy, XTC

Contributor Information and Disclosures

Author

Joseph Tonkonogy, MD, PhD, Clinical Professor of Psychiatry and Neurology, University of Massachusetts Medical School; Consulting Staff, Departments of Psychiatry and Neurology, University of Massachusetts Medical Center
Joseph Tonkonogy, MD, PhD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Neuropsychiatric Association, International Neuropsychological Society, Massachusetts Medical Society, Royal Society of Medicine, Society for Neuroscience, and United Council for Neurologic Subspecialties, Certification Behavioral Neurology and Neuropsychiatry
Disclosure: Nothing to disclose.

Coauthor(s)

Darius P Sholevar, MD, Fellow, Cardiovascular Disease, Albert Einstein Medical Center
Disclosure: Nothing to disclose.

Medical Editor

Alan D Schmetzer, MD, Professor, Vice-Chair for Education, and Director of Residency Training in General and Addiction Psychiatry, Department of Psychiatry, Indiana University School of Medicine
Alan D Schmetzer, MD is a member of the following medical societies: American Academy of Addiction Psychiatry, American Academy of Clinical Psychiatrists, American Academy of Psychiatry and the Law, American College of Physician Executives, American Medical Association, American Neuropsychiatric Association, American Psychiatric Association, and Association for Convulsive Therapy
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Iqbal Ahmed, MBBS, Professor, Department of Psychiatry, John A Burns School of Medicine, University of Hawaii
Iqbal Ahmed, MBBS is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Speaking and teaching; Northstar Grant/research funds Research; Novartis Grant/research funds research; Pfizer  Speaking and teaching; Sanofi-avetis Grant/research funds research; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)